|1.||Takahashi, S: 3 articles (07/2001 - 07/2000)|
|2.||Horikomi, K: 3 articles (07/2001 - 07/2000)|
|3.||Takahashi, Shinji: 1 article (10/2002)|
|4.||Takagi, Kaori: 1 article (10/2002)|
|5.||Horikomi, Kazutoshi: 1 article (10/2002)|
|6.||Karasawa, Jun-ichi: 1 article (10/2002)|
|7.||Wang, HuiDong: 1 article (09/2002)|
|8.||Takigawa, Morikuni: 1 article (09/2002)|
|9.||Takagi, K: 1 article (07/2001)|
|10.||Yamauchi, K: 1 article (08/2000)|
|1.||Schizophrenia (Dementia Praecox)
08/01/1999 - "Therefore, MS-377 could be a novel antipsychotic agent with clinical efficacy for overall symptoms of schizophrenia including its negative symptoms and without EPS liability."
07/28/2000 - "MS-377 is a novel selective sigma(1) ligand, currently being developed for the treatment of schizophrenia. "
08/25/2000 - "These data indicate that the PCP-induced disruption of PPI in rats would be, at least partially, mediated by sigma receptors and MS-377 could be a novel anti-psychotic agent with clinical efficacy for the sensorimotor-gating deficit in schizophrenia."
09/01/2002 - "The results agree with the interpretation that sigma ligands may directly or indirectly modulate NMDA receptor complex functions, and may suggest that MS-377 might be therapeutically useful in cases of PCP-induced psychosis or schizophrenia."
07/14/2000 - "MS-377 ((R)-(+)-1-(4-chlorophenyl)-3-[4-(2-methoxyethyl)piperazin-1-yl]++ +methy l-2-pyrrolidinone L-tartrate) is a novel selective sigma receptor ligand, currently being developed for the treatment of schizophrenia. "
07/01/2001 - "MS-377, haloperidol, sultopride and risperidone dose-dependently inhibited PCP-induced rearing and hyperlocomotion, but did not antagonize PCP-induced ataxia. "
07/01/2001 - "In the present study, we examined the effects of two potent and selective sigma1-ligands, MS-377 and N,N-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl) ethylamine (NE-100), on PCP-induced rearing behaviour, hyperlocomotion and ataxia in comparison with the currently available antipsychotic agents with affinity for D2 receptors, haloperidol, sultopride and risperidone. "
10/01/2002 - "In contrast, MS-377 did not affect the catalepsy induction by these drugs. "
08/01/1999 - "MS-377 was inactive in models of extrapyramidal side effect (EPS) liability such as prevention of Apo-induced stereotypy and induction of catalepsy in rats. "
10/01/2002 - "The effects of MS-377 on haloperidol- or sultopride-induced inhibition of apomorphine-induced climbing behavior and catalepsy were investigated in mice and rats, respectively. "
|1.||sigma Receptors (sigma Receptor)
|4.||Risperidone (Risperdal Consta)
|5.||Antipsychotic Agents (Antipsychotics)
|8.||Phencyclidine (Angel Dust)